Naz Rahman
Stock Analyst at Maxim Group
(0.22)
# 4,372
Out of 5,182 analysts
38
Total ratings
15.15%
Success rate
-40.07%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $575 | $423.92 | +35.64% | 2 | Mar 18, 2026 | |
| NXGL NEXGEL | Maintains: Buy | $6 → $2 | $0.58 | +244.17% | 2 | Mar 12, 2026 | |
| SCNX Scienture Holdings | Initiates: Buy | $1.5 | $0.40 | +273.88% | 1 | Feb 24, 2026 | |
| KZIA Kazia Therapeutics | Maintains: Buy | $15 → $20 | $13.39 | +49.37% | 1 | Oct 2, 2025 | |
| AYTU Aytu BioPharma | Maintains: Buy | $9 → $7 | $2.63 | +166.16% | 2 | Sep 25, 2025 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $0.57 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $8.54 | +99.06% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $0.60 | +12,435.52% | 2 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $30.00 | +133.33% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $0.90 | - | 2 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $5.37 | - | 4 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $8 | $1.99 | +302.01% | 7 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.89 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $18.47 | +143.64% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $6.21 | +2,154.43% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.55 | - | 3 | Nov 17, 2023 |
Vertex Pharmaceuticals
Mar 18, 2026
Upgrades: Buy
Price Target: $575
Current: $423.92
Upside: +35.64%
NEXGEL
Mar 12, 2026
Maintains: Buy
Price Target: $6 → $2
Current: $0.58
Upside: +244.17%
Scienture Holdings
Feb 24, 2026
Initiates: Buy
Price Target: $1.5
Current: $0.40
Upside: +273.88%
Kazia Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $13.39
Upside: +49.37%
Aytu BioPharma
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $2.63
Upside: +166.16%
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.57
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $8.54
Upside: +99.06%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $0.60
Upside: +12,435.52%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $30.00
Upside: +133.33%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.90
Upside: -
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $5.37
Upside: -
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $1.99
Upside: +302.01%
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.89
Upside: -
Jul 26, 2024
Initiates: Buy
Price Target: $45
Current: $18.47
Upside: +143.64%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $6.21
Upside: +2,154.43%
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.55
Upside: -